Assessment of response to therapy in prostate cancer (PCa) patients relies on a combination of clinical parameters, the biochemical response as reflected by a change in serum prostate-specific antigen (PSA) levels, and on the morphological assessment on computerized tomographic (CT) imaging using the Response Evaluation Criteria in Solid Tumors (RECIST) [1–4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.